Search
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnIt was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults. … [L31863] Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1ε, distinguishing it from other lymphoma treatments.
Quaternium-15
go.drugbank.com/drugs/DB14198ApprovedIn 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326]. … Sensitivity to Quaternium-15 may be identified with a clinical patch test.
Brilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.
Synonyms: Brilliant blue G, Coomassie Brilliant Blue GTechnetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawn[L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981. … [L1137] The radiopharmaceuticals based on technetium-99m are widely used for diagnostic purposes because 99mTc has a versatile chemistry which allows it to produce an extense variety of complexes with
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...
VIR-5500
go.drugbank.com/drugs/DB28578InvestigationalVIR-5500 is under investigation in clinical trial NCT05997615 (Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer).
Synonyms: AMX-500Voxelotor
go.drugbank.com/drugs/DB14975Approvedto 20 million others worldwide. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Colestipol
go.drugbank.com/drugs/DB00375Approved. may not be good candidates for using the agent owing to its physical effects on the gut. … ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Potassium bitartrate
go.drugbank.com/drugs/DB11107ApprovedInvestigationalPotassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120] … It is obtained as a byproduct of wine manufacture during the fermentation process.